Impact of Timely Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor After 12-Month Complete Cytogenetic Response Failure: A Chart Review Analysis

Authors:

Abstract
No abstract available
Funding Information
  • Novartis Pharmaceuticals Corporation

This publication has 14 references indexed in Scilit: